Skip to search formSkip to main contentSkip to account menu

ambamustine

Known as: 3-(4-fluorophenyl)Ala-3-(3-bis(2-chloroethyl)aminophenyl)Ala-Met ethyl ester, 3-(4-fluorophenyl)alanyl-3-(3-bis(2-chloroethyl)aminophenyl)alanyl-methionine ethyl ester, N-(3-(m-(Bis(2-chloroethyl)amino)phenyl)-N-(3-(p-fluorophenyl)-L-alanyl)-L-alanyl)-L-methionine, Ethyl Ester 
A tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity.
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antineoplastic AgentsNitrogen Mustard Compounds

Narrower (1)

PTT 119

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Ambamustine. PTT119.
2000
2000
Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study.
Despite a high probability of response to first-line chemotherapy, most patients with small-cell lung cancer (SCLC) will… 
1998
1998
Use of the comet test in the evaluation of multidrug resistance of human cell lines
The comet test is a reported method for measuring DNA damage in individual mammalian cells. In the present report, the ability of… 
1997
1997
199 Second line chemotherapy with ambamustine in small cell lung cancer (SCLC): A phase II FONICAP trial
1996
1996
Optimized preparation of deca(L-alanyl)-L-valinamide by 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase synthesis on polyethylene glycol-polystyrene (PEG-PS) graft supports, with 1,8-diazobicyclo [5…
Deca(L-alanyl)-L-valinamide is known to be a challenging model target for solidphase peptide synthesis, due to its hydrophobicity… 
1994
1994
Limiting dilution analysis of a novel tripeptide anticancer agent Ambamustine (PTT-119): effect on K-562, CCRF-SB and multidrug resistant LoVo-Dk cell lines.
Cell suspensions of normal human bone marrow were mixed with human acute lymphoblastic or myelogenous leukemic cells of the CCRF… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)